Approximately 25% of patients with monoclonal gammopathy of undetermined significance (MGUS) eventually develop multiple myeloma (MM) or a related plasma cell disorder that is universally fatal. In this report, we examine the changes that occur in the clonal plasma cell that are likely to be important in the progression of MGUS to active myeloma.
Methods
Studies that investigate the mechanisms involved in the multistep pathogenesis of monoclonal gammopathies are reviewed. Cytokines such as IL- 6 and IL-1β, adhesion molecules, viruses, and oncogenes including ras, bcl-2, Rb, and p53 are discussed.
Results
IL-1β is produced by plasma cells from virtually all MM patients but is undetectable in most MGUS patients. IL-1β has potent osteoclast activating factor activity, can increase the expression of adhesion molecules, and can induce paracrine IL-6 production. The increased production of adhesion molecules could explain why myeloma cells are found predominantly in the bone marrow. Subsequently, these “fixed” monoclonal plasma cells could now stimulate osteoclasts through the production of IL-1β and paracrine generation of IL-6 resulting in osteolytic disease. With continued progression of the myeloma, the monoclonal plasma cells may later acquire the ability to produce IL-6 in an autocrine fashion that will be manifested clinically by an elevated labeling index.
Conclusions
A better understanding of the progression of MGUS to myeloma may lead to novel therapeutic strategies to prevent the development of MM.
Get full access to this article
View all access options for this article.
References
1.
KyleR.A., LustJ.A.Monoclonal gammopathies of undetermined significance. Semin Hematol.1989; 26: 176–200.
2.
GreippP.R., LustJ.A.Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Stem Cells.1995; 13: 10–21.
3.
KyleR.A.“Benign” monoclonal gammopathy: after 20 to 35 years of follow-up. Mayo Clinic Proc.1993; 68: 26–36.
4.
KyleR.A., BeardC.M., O'FallonW.M.Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. J Clin Oncol.1994; 12: 1577–1583.
5.
KishimotoT.The biology of interleukin-6. Blood.1989; 74: 1–10.
6.
PotterM.Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematol Oncol Clin North Am.1992; 6: 211–223.
7.
PotterM., SklarM.D., RoweW.P.Rapid viral induction of plasmacytomas in pristane-primed BALB-c mice. Science.1973; 182: 592–594.
ClynesR., WaxJ., StantonL.W.Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus. Proc Natl Acad Sci U S A.1988, 85: 6067–6071.
10.
KawanoM., HiranoT., MatsudaT.Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature.1988; 332: 83–85.
11.
SchwabG., SiegallC.B., AardenL.A.Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood.1991; 77: 587–593.
12.
BatailleR., JourdanM., ZhangX.G.Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest.1989; 84: 2008–2011.
13.
ZhangX.G., KleinB., BatailleR.Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood.1989; 74: 11–13.
14.
KleinB., WijdenesJ., ZhangX.G.Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood.1991; 78: 1198–1204.
15.
BatailleR., WijdenesJ., AardenL.Murine anti-interleukin-6 (IL-6) monoclonal antibody (MoAb) therapy in patients with advanced multiple myeloma (MM). Blood.1991, 78: 129a.
16.
LustJ.A., DonovanK.A., KlineM.P.Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine.1992; 4: 96–100.
17.
LustJ.A., JelinekD.F., DonovanK.A.Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R). Curr Top Microbiol Immunol.1995; 194: 199–206.
18.
GaillardJ.P., BatailleR., BraillyH.Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol.1993; 23: 820–824.
19.
KleinB., ZhangX.G., JourdanM.Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by Interleukin-6. Blood.1989; 73: 517–526.
20.
PortierM., RajzbaumG., ZhangX.G.In vivo interleukin-6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol.1991; 21: 1759–1762.
21.
HataH., XiaoH., PetrucciM.T.Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood.1993; 81: 3357–3364.
22.
DonovanK.A., LacyM.Q., KlineM.P.Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia.1998; 12: 593–600.
23.
WestendorfJ.J., AhmannG.J., GreippP.R.Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interluekin-6. Leukemia.1996; 10: 866–876.
24.
BagbyG.C.Jr. Interleukin-1 and hematopoiesis. Blood Rev.1989; 3: 152–161.
25.
CarterA., MerchavS., Silvian-DraxlerI.The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol.1990; 74: 424–431.
26.
LichtensteinA., BerensonJ., NormanD.Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood.1989; 74: 1266–1273.
27.
KleinB., LuZ.Y., GaillardJ.P.Inhibiting IL-6 in human multiple myeloma. Curr Top Microbiol Immunol.1992; 182: 237–244.
28.
CozzolinoF., TorciaM., AldinucciD.Production of interleukin-1 by bone marrow myeloma cells. Blood.1989; 74: 380–387.
29.
YamamotoI., KawanoM., SoneT.Production of interleukin-1beta, a potent bone resorbing cytokine, by cultured human myeloma cells. Cancer Res.1989; 49: 4242–4246.
30.
TorciaM., LucibelloM., VannierE.Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp Hematol.1996; 24: 868–874.
31.
HawleyT.S., LachB., BurnsB.F.Expression of retrovirally transduced IL-1alpha in IL-6-dependent B cells: a murine model of aggressive multiple myeloma. Growth Factors.1991; 5: 327–338.
32.
HawleyR.G., WangM.H., FongA.Z.Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas. Clin Exp Metastasis.1993; 11: 213–226.
33.
HamiltonM.S., BallJ., BromidgeE.Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br J Haematol.1991; 78: 60–65.
34.
MiyakeK., WeissmanI.L., GreenbergerJ.S.Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J Exp Med.1991; 173: 599–607.
35.
Van CampB., DurieB.G., SpierC.Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood.1990; 6: 377–382.
36.
LewinsohnD.M., NaglerA., GinztonN.Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. Blood.1990; 75: 589–595.
37.
DrachJ., GattringerC., HuberH.Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol.1991; 83: 418–422.
38.
Van RietI., Van CampB.The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma.1993; 9: 441–452.
39.
CollinsT., ReadM.A., NeishA.S.Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J.1995; 9: 899–909.
40.
HuangY.W., RichardsonJ.A., VitettaE.S.Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res.1995; 55: 610–616.
41.
SonneveldP., DurieB.G., LokhorstH.M.Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br J Haematol.1993; 83: 63–67.
42.
HaradaH., KawanoM.M., HuangN. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood.1993; 81: 2658–2663.
43.
San MiguelJ.F., AlmeidaJ., OcqueteauM.Detection of two subpopulations of plasma cells in MGUS patients: utility in the differential diagnosis with multiple myeloma. Blood.1996; 88: 640a.
44.
DinarelloC.A.Biologic basis for interleukin-1 in disease. Blood.1996; 87: 2095–2147.
45.
RettigM.B., MaH.J., VescioR.A.Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science.1997; 276: 1851–1854.
46.
CorleyP.A.Induction of interleukin-1 and glucocorticoid hormones by HIV promotes viral replication and links human chromosome 2 to AIDS pathogenesis: genetic mechanisms and therapeutic implications. Med Hypotheses.1997; 48: 415–421.
47.
BeaulieuA.D., PaquinR., GosselinJ.Epstein-Barr virus modulates de novo protein synthesis in human neutrophils. Blood.1995; 86: 2789–2798.
48.
BitkoV., VelazquezA., YangL.Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Virology.1997; 232: 369–378.
GroganT.M., DurieB.G., LomenC.Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture and kinetic features. Blood.1987; 70: 932–942.
51.
TerstappenL.W., JohnsenS., Segers-NoltenI.M.Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood.1990; 76: 1739–1747.
52.
BastE.J., van CampB., ReynaertP.Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol.1982; 47: 677–682.
53.
KubagawaH., VoglerL.B., CapraJ.D.Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med.1979; 150: 792–807.
JoshuaD.E., IoannidisR., BrownR.Multiple myeloma: relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes. Am J Hematol.1988; 29: 5–11.
56.
KingM.A., NelsonD.S.Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic and functional studies of cells from blood and bone marrow. Blood.1989; 73: 1925–1935.
57.
BerguiL., SchenaM., GaidanoG.Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med.1989; 170: 613–618.
58.
WitzigT.E., DhodapkarM.V., KyleR.A.Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer.1993; 72: 108–113.
59.
DewaldG.W., KyleR.A., HicksG.A.The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia or amyloidosis. Blood.1985; 66: 380–390.
60.
FertiA., PananiA., ArapakisG.Cytogenetic study in multiple myeloma. Cancer Genet Cytogenet.1984; 12: 247–253.
61.
JelinekD.F., AhmannG.J., GreippP.R.Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res.1993; 53: 5320–5327.
62.
DrachJ., AngerlerJ., SchusterJ.Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood.1995; 86: 3915–3921.
63.
BergsagelP.L., ChesiM., NardiniE.Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci U S A.1996; 93: 13931–13936.
64.
ChesiM., BergsagelP.L., BrentsL.A.Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood.1996; 88: 674–681.
65.
ChesiM., NardiniE., BrentsL.A.Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet.1997; 16: 260–264.
66.
NishidaK., TamuraA., NakazawaN.The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood.1997; 90: 526–534.
67.
DurieB.G.M., MasonD.Y., GilesF.Expression of the BCL-2 oncogene protein in multiple myeloma. Blood.1990; 76: 347a.
68.
YangE., KorsmeyerS.J.Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood.1996; 88: 386–401.
69.
SchwarzeM.M., HawleyR.G.Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-XL. Cancer Res.1995; 55: 2262–2265.
TsuchiyaH., EpsteinJ., SelvanayagamP.Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma. Blood.1988; 72: 796–800.
72.
SeremetisS., InghiramiG., FerreroD.Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes. Science.1989; 243: 660–663.
73.
BilladeauD., JelinekD.F., ShahN.Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res.1995; 55: 3640–3646.
74.
MazarsG.R., PortierM., ZhangX.G.Mutations of the p53 gene in human myeloma cell lines. Oncogene.1992; 7: 1015–1018.
75.
PortierM., MolesJ.P., MazarsG.R.p53 and RAS gene mutations in multiple myeloma. Oncogene.1992; 7: 2539–2543.
76.
TricotG., DaoD., GazittY.Deletion of the retinoblastoma gene (Rb-1) in multiple myeloma. Blood.1993; 82: 261a.
77.
SanthanamU., RayA., SehgalP.B.Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A.1991; 88: 7605–7609.
78.
SatoK., TsuchiyaM., SaldanhaJ.Reshaping a human antibody to inhibit the interleukin 6 dependent tumor cell growth. Cancer Res.1993; 53: 851–856.
79.
SavinoR., CiapponiL., LahmA.Rational design of a receptor super-antagonist of human interleukin-6. EMBO J.1994; 13: 5863–5870.
80.
FanslowW.C., SimsJ.E., SassenfeldH.Regulation of alloreactivity in vivo by a soluble form of the interleukin-1 receptor. Science.1990; 248: 739–742.
81.
DinarelloC.A., ThompsonR.C.Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today.1991; 12: 404–410.
82.
KreitmanR.J., SiegallC.B., FitzGeraldD.J.Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood.1992; 79: 1775–1780.
83.
KaminskiM.S., ZasadnyK.R., FrancisI.R.Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med.1993; 329: 459–465.
